Nils Nicolay: Our new multicenter data will help to further clarify the role of definitive chemoradiation in elderly HNSCC patients
Nils Nicolay, Professor and Chair of the Department of Radiation Oncology at the University of Leipzig Medical Center, shared on LinkedIn:
“Another great international collaborative work by the SENIOR HNSCC investigators just published in the Red Journal. Our new multicenter data will help to further clarify the role of definitive chemoradiation in elderly HNSCC patients:
– Cisplatin is the drug of choice also for elderly HNSCC patients undergoing chemoradiation – if they can tolerate it!
– Elderly patients too benefit from a cumulative cisplatin dose of at least 200 mg/m2 – regarding their locoregional control and their overall survival!
More interesting data on elderly HNSCC patients is coming very soon – and the collaborative group is growing and growing…
Again, a massive thank you to our colleagues and collaborators who have contributed to the success of the project and the publication of these very important data.”
For the article click here.
Source: Nils Nicolay/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023